First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland

Belzutifan is a new HIF-α inhibitor mainly used in two different indications: von Hippel–Lindau syndrome-associated renal cell carcinoma, haemangioblastomas and pancreatic neuroendocrine tumours, as well as sporadic advanced pre-treated renal cell carcinoma. Although efficacy has been demonstrated i...

Full description

Bibliographic Details

Published in:	Current Oncology
Main Authors:	Tobias Peres, Stefanie Aeppli, Stefanie Fischer, Thomas Hundsberger, Christian Rothermundt
Format:	Article
Language:	English
Published:	MDPI AG 2025-01-01
Subjects:	belzutifan HIF-α inhibitor von Hippel–Lindau syndrome renal cell carcinoma haemangioblastomas case series
Online Access:	https://www.mdpi.com/1718-7729/32/2/64